Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (21-30 of 272) with videos related to

Pageof 28
Sort By:
Future Oncology (London, England)|August 29, 2015
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
RETaliation-Tackling Rare Resistance Alterations to OsimertinibMatthew G Krebs, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|September 16, 2015
Systemic therapy for pulmonary carcinoidsDiego Marquez-Medina, Sanjay Popat
Journal of the National Cancer Institute|June 2, 2005
Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysisSanjay Popat, Ian E Smith
Nature Clinical Practice. Oncology|March 28, 2008
Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effectsSanjay Popat, Ian E Smith
Clinical Medicine (London, England)|July 10, 2003
Polymorphic sequence variants in medicine: a challenge and an opportunityShirley V Hodgson, Sanjay Popat
Future Oncology (London, England)|February 2, 2016
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?Sanjay Popat, Mark J Ratain
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2016
Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?Timothy A Yap, Sanjay Popat
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2013
The role of afatinib in the management of non-small cell lung carcinomaTimothy A Yap, Sanjay Popat
Pageof 28

Showing results (21-30 of 272) with videos related to

Sort By:
Pageof 28
Future Oncology (London, England)|August 29, 2015
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
RETaliation-Tackling Rare Resistance Alterations to OsimertinibMatthew G Krebs, Sanjay Popat
Lung Cancer (Amsterdam, Netherlands)|September 16, 2015
Systemic therapy for pulmonary carcinoidsDiego Marquez-Medina, Sanjay Popat
Journal of the National Cancer Institute|June 2, 2005
Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysisSanjay Popat, Ian E Smith
Nature Clinical Practice. Oncology|March 28, 2008
Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effectsSanjay Popat, Ian E Smith
Clinical Medicine (London, England)|July 10, 2003
Polymorphic sequence variants in medicine: a challenge and an opportunityShirley V Hodgson, Sanjay Popat
Future Oncology (London, England)|February 2, 2016
Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancerDiego Marquez-Medina, Sanjay Popat
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Dose optimization of sotorasib: Has the burden of proof for the labeled dose been met?Sanjay Popat, Mark J Ratain
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2016
Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?Timothy A Yap, Sanjay Popat
Expert Opinion on Drug Metabolism & Toxicology|August 30, 2013
The role of afatinib in the management of non-small cell lung carcinomaTimothy A Yap, Sanjay Popat
Pageof 28